Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.

PubWeight™: 1.97‹?› | Rank: Top 2%

🔗 View Article (PMC 2701658)

Published in Science on September 05, 2008

Authors

Mario L Santiago1, Mauricio Montano, Robert Benitez, Ronald J Messer, Wes Yonemoto, Bruce Chesebro, Kim J Hasenkrug, Warner C Greene

Author Affiliations

1: Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA.

Articles citing this

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42

Immunology and the elusive AIDS vaccine. Nature (2010) 2.26

Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res (2009) 1.94

Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86

Murine endogenous retroviruses. Cell Mol Life Sci (2008) 1.85

Susceptibility of xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction factors. Proc Natl Acad Sci U S A (2010) 1.71

APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe (2010) 1.67

Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology (2009) 1.51

Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48

Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity (2011) 1.42

The mouse "xenotropic" gammaretroviruses and their XPR1 receptor. Retrovirology (2010) 1.35

APOBECs and virus restriction. Virology (2015) 1.27

Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol (2009) 1.23

Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc Natl Acad Sci U S A (2013) 1.19

The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol (2009) 1.17

Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog (2011) 1.16

Biochemical and biological studies of mouse APOBEC3. J Virol (2014) 1.14

The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol (2010) 1.09

APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology (2009) 1.08

The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med (2009) 1.07

A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog (2012) 1.06

Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection. J Virol (2009) 1.05

Host restriction factors in retroviral infection: promises in virus-host interaction. Retrovirology (2012) 1.05

Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response. PLoS Pathog (2011) 1.05

Effects of acute and chronic murine norovirus infections on immune responses and recovery from Friend retrovirus infection. J Virol (2009) 1.04

Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice. J Virol (2010) 1.04

Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog (2010) 1.03

Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol (2010) 0.99

Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol (2009) 0.98

APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol (2013) 0.97

Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection. Proc Natl Acad Sci U S A (2014) 0.97

Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. Clin Microbiol Rev (2012) 0.97

Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. J Neurosci (2015) 0.96

Accessories to the crime: recent advances in HIV accessory protein biology. Curr HIV/AIDS Rep (2009) 0.96

APOBEC3 proteins inhibit LINE-1 retrotransposition in the absence of ORF1p binding. Ann N Y Acad Sci (2009) 0.95

Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes. Cancer Epidemiol Biomarkers Prev (2009) 0.93

Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol (2010) 0.93

Two genetic determinants acquired late in Mus evolution regulate the inclusion of exon 5, which alters mouse APOBEC3 translation efficiency. PLoS Pathog (2012) 0.92

Powerful mutators lurking in the genome. Philos Trans R Soc Lond B Biol Sci (2009) 0.92

Studies on the restriction of murine leukemia viruses by mouse APOBEC3. PLoS One (2012) 0.92

Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. J Immunol (2014) 0.90

IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3. J Immunol (2013) 0.90

APOBEC3 Proteins in Viral Immunity. J Immunol (2015) 0.89

Increased APOBEC3G and APOBEC3F expression is associated with low viral load and prolonged survival in simian immunodeficiency virus infected rhesus monkeys. Retrovirology (2011) 0.89

Humoral immunity in the Friend retrovirus infection model. Immunol Res (2013) 0.87

Are viruses inhibited by APOBEC3 molecules from their host species? PLoS Pathog (2009) 0.87

Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo. PLoS Pathog (2014) 0.87

Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development. J Virol (2013) 0.87

Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J Biol Chem (2010) 0.86

Zinc-finger antiviral protein mediates retinoic acid inducible gene I-like receptor-independent antiviral response to murine leukemia virus. Proc Natl Acad Sci U S A (2013) 0.86

Restriction by SAMHD1 Limits cGAS/STING-Dependent Innate and Adaptive Immune Responses to HIV-1. Cell Rep (2016) 0.86

APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans. Mol Biol Int (2012) 0.84

Multi-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation. Retrovirology (2008) 0.84

Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection. Virology (2013) 0.83

Mouse knockout models for HIV-1 restriction factors. Cell Mol Life Sci (2014) 0.83

Mice of the resistant H-2(b) haplotype mount broad CD4(+) T cell responses against 9 distinct Friend virus epitopes. Virology (2014) 0.82

The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. PLoS One (2012) 0.82

Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc (2009) 0.81

Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity. J Virol (2014) 0.81

Tetherin/BST-2 promotes dendritic cell activation and function during acute retrovirus infection. Sci Rep (2016) 0.80

N-linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins. J Virol (2014) 0.80

A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection. J Virol (2015) 0.80

Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo. Virology (2014) 0.80

Fv1 restriction and retrovirus vaccine immunity in Apobec3-deficient 129P2 mice. PLoS One (2013) 0.79

Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response. J Virol (2015) 0.79

Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases. J Virol (2011) 0.79

An interleukin-1 beta-encoding retrovirus exhibits enhanced replication in vivo. J Virol (2014) 0.79

Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization. Vaccine (2013) 0.78

Incorporation of mouse APOBEC3 into murine leukemia virus virions decreases the activity and fidelity of reverse transcriptase. J Virol (2014) 0.78

Retroviral immunology: lessons from a mouse model. Immunol Res (2009) 0.78

Impaired B cell function during viral infections due to PTEN-mediated inhibition of the PI3K pathway. J Exp Med (2017) 0.77

Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk. J Virol (2009) 0.77

In Vivo Examination of Mouse APOBEC3- and Human APOBEC3A- and APOBEC3G-Mediated Restriction of Parvovirus and Herpesvirus Infection in Mouse Models. J Virol (2016) 0.76

How Active Are Porcine Endogenous Retroviruses (PERVs)? Viruses (2016) 0.76

Cellular HIV-1 inhibition by truncated old world primate APOBEC3A proteins lacking a complete deaminase domain. Virology (2014) 0.76

Antiretroviral restriction factors in mice. Virus Res (2014) 0.76

APOBEC3 enzymes restrict marginal zone B cells. Eur J Immunol (2015) 0.76

Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies. J Exp Med (2017) 0.75

Filariae-Retrovirus Co-infection in Mice is Associated with Suppressed Virus-Specific IgG Immune Response and Higher Viral Loads. PLoS Negl Trop Dis (2016) 0.75

Type I interferon signaling is required for the APOBEC3/Rfv3-dependent neutralizing antibody response but not innate retrovirus restriction. Retrovirology (2017) 0.75

T Cell Production of IFNγ in Response to TLR7/IL-12 Stimulates Optimal B Cell Responses to Viruses. PLoS One (2016) 0.75

B Cell Requirement for Robust Regulatory T Cell Responses to Friend Retrovirus Infection. MBio (2017) 0.75

Articles cited by this

Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83

HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40

HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42

Positional cloning of the mouse retrovirus restriction gene Fv1. Nature (1996) 7.01

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35

The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27

Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet (1999) 2.48

Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28

Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95

Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69

Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production. J Exp Med (1979) 1.63

Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol (2008) 1.50

Lymphocyte deficiencies increase susceptibility to friend virus-induced erythroleukemia in Fv-2 genetically resistant mice. J Virol (1999) 1.32

H-2D control of recovery from Friend virus leukemia: H-2D region influences the kinetics of the T lymphocyte response to Friend virus. J Exp Med (1983) 1.28

Studies on the control of antibody synthesis. VI. Effect of antigen dose and time after immunization on antibody affinity and heterogeneity in the mouse. Clin Exp Immunol (1974) 1.22

Studies of immune responsiveness and unresponsiveness to the p-azobenzenearsonate (ABA) hapten. Immunol Rev (1984) 1.21

Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol (1995) 1.18

Fine mapping of the friend retrovirus resistance gene, Rfv3, on mouse chromosome 15. J Virol (1999) 1.10

The role of CD4 T cells in the pathogenesis of murine AIDS. J Virol (2006) 0.98

Friend virus replication in normal and immunosuppressed C57BL/6 mice. Virology (1990) 0.97

Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS (2005) 0.97

Low antigen dose favours selection of somatic mutants with hallmarks of antibody affinity maturation. Immunology (1998) 0.95

Infectivity of retroviral DNA in vivo. J Acquir Immune Defic Syndr (1992) 0.93

Articles by these authors

The challenge of finding a cure for HIV infection. Science (2009) 8.41

HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42

Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 6.88

A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49

Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28

Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91

NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J (2005) 4.35

The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol (2008) 4.27

HIV vaccine research: the way forward. Science (2008) 3.86

NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol (2005) 3.50

Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell (2010) 3.42

Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity (2004) 3.10

HIV latency. Cold Spring Harb Perspect Med (2011) 2.90

Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem (2009) 2.80

HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72

IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science (2013) 2.68

High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A (2006) 2.54

Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem (2004) 2.47

The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol (2007) 2.41

The cationic properties of SEVI underlie its ability to enhance human immunodeficiency virus infection. J Virol (2008) 2.38

Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrP(Sc)) into contiguous membranes. EMBO J (2002) 2.16

Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol (2004) 2.06

Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol (2005) 2.02

p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem (2004) 2.01

Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86

Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med (Berl) (2003) 1.79

Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med (2006) 1.77

Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol (2007) 1.74

Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe (2011) 1.72

Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI. Retrovirology (2010) 1.70

Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog (2007) 1.70

In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog (2007) 1.70

Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem (2006) 1.68

An integrated overview of HIV-1 latency. Cell (2013) 1.68

Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A (2012) 1.65

BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood (2013) 1.57

Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol (2007) 1.50

Biomedicine. A view from the top--prion diseases from 10,000 feet. Science (2003) 1.48

Regulation of HIV-1 latency by T-cell activation. Cytokine (2007) 1.48

Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47

Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem (2006) 1.42

Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection. J Virol (2011) 1.42

Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol (2005) 1.41

Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol (2007) 1.41

Aminoquinoline surfen inhibits the action of SEVI (semen-derived enhancer of viral infection). J Biol Chem (2009) 1.39

Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis (2005) 1.39

Slipping through the door: HIV entry into the nucleus. Microbes Infect (2002) 1.39

Human T-cell lymphotropic virus type 1 tax induction of biologically Active NF-kappaB requires IkappaB kinase-1-mediated phosphorylation of RelA/p65. J Biol Chem (2004) 1.38

Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe (2008) 1.35

Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages. J Virol (2005) 1.34

HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology (2004) 1.34

Susceptibilities of nonhuman primates to chronic wasting disease. Emerg Infect Dis (2009) 1.33

Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog (2011) 1.31

Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility. Hum Mol Genet (2011) 1.31

In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells. J Immunol (2006) 1.30

Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation of infectivity during four passages. J Infect Dis (2002) 1.28

Gene expression alterations in brains of mice infected with three strains of scrapie. BMC Genomics (2006) 1.27

Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol (2004) 1.26

Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions. Proc Natl Acad Sci U S A (2011) 1.26

Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci U S A (2011) 1.26

CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection. J Virol (2005) 1.26

Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Ann Neurol (2004) 1.24

Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. PLoS Pathog (2013) 1.23

Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. Science (2006) 1.23

Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J Immunol (2011) 1.23

A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One (2012) 1.23

Human immunodeficiency virus fusion to dendritic cells declines as cells mature. J Virol (2006) 1.22

Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A (2004) 1.20

NF-kappaB/Rel regulates inhibitory and excitatory neuronal function and synaptic plasticity. Mol Cell Biol (2006) 1.20

The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathog (2008) 1.18

Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem (2011) 1.18

MCP-1 and CCR2 contribute to non-lymphocyte-mediated brain disease induced by Fr98 polytropic retrovirus infection in mice: role for astrocytes in retroviral neuropathogenesis. J Virol (2004) 1.17

Novel targets for HIV therapy. Antiviral Res (2008) 1.15

Dynamic roles for NF-κB in HTLV-I and HIV-1 retroviral pathogenesis. Immunol Rev (2012) 1.14

HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology (2002) 1.14

Rodent cells support key functions of the human immunodeficiency virus type 1 pathogenicity factor Nef. J Virol (2005) 1.13

Lymphotoxin-alpha- and lymphotoxin-beta-deficient mice differ in susceptibility to scrapie: evidence against dendritic cell involvement in neuroinvasion. J Virol (2002) 1.13

Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol (2006) 1.12

Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J Virol (2003) 1.11

Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax. J Biol Chem (2005) 1.10

The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol (2010) 1.09

Lactate dehydrogenase-elevating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells. PLoS One (2009) 1.08